-
SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data
- Dung Nguyen1 , Peter Simmonds1 , Maurice Steenhuis2 , Elise Wouters3 , Daniel Desmecht4 , Mutien Garigliany4 , Marta Romano5 , Cyril Barbezange6 , Piet Maes7 , Bram Van Holm7 , Joaquín Mendoza8 , Salvador Oyonarte9 , Anders Fomsgaard10 , Ria Lassaunière10 , Eva Zusinaite11 , Katarina Resman Rus12 , Tatjana Avšič-Županc12 , Johan HJ Reimerink13 , Fiona Brouwer13 , Marieke Hoogerwerf13 , Chantal BEM Reusken13 , Gunnveig Grodeland14 , Sophie Le Cam15 , Pierre Gallian15,16 , Abdennour Amroun16 , Nadège Brisbarre16,17 , Christophe Martinaud18 , Isabelle Leparc Goffart19 , Hubert Schrezenmeier20,21 , Hendrik B Feys3 , C Ellen van der Schoot2 , Heli Harvala22,23
-
View Affiliations Hide AffiliationsAffiliations: 1 University of Oxford, Oxford, United Kingdom 2 Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Amsterdam, Netherlands 3 Transfusion Research Centre, Belgian Red Cross-Flanders, Ghent, Belgium 4 Department of Pathology, Faculty of Veterinary Medicine, Liège University, Liège, Belgium 5 Immune Response service, Sciensano, Brussels, Belgium 6 National Influenza Centre, Sciensano, Brussels, Belgium 7 KU Leuven, Rega Institute, Clinical and Epidemiological Virology, Leuven, Belgium 8 Vircell SL, Granada, Spain 9 Andalusian Network of Transfusion Medicine, Tissues and Cells, Sevilla, Spain 10 Virus and Microbiological Special Diagnostics, Statens Serum Institute, Copenhagen, Denmark 11 Tartu University Institute of Technology, Tartu, Estonia 12 Institute of Microbiology and Immunology, Ljubljana, Slovenia 13 Centre for Infectious Disease Control, WHO COVID-19 Reference Laboratory, RIVML, Bilthoven, the Netherlands 14 Dep. of Immunology, University of Oslo and Oslo University Hospital, Oslo, Norway 15 Etablissement Français du Sang, La Plaine Saint Denis, France 16 Unité des Virus Émergents (Aix-Marseille University – IRD 190 – Inserm 1207 – IHU Méditerranée Infection), Marseille, France 17 Etablissement français du Sang Provence Alpes Côte d’Azur et Corse, Marseille, France 18 Centre de Transfusion Sanguine des Armées, Clamart, France 19 Unité de Virologie, Institut de Recherche Biomédicale des Armées, Marseille, France 20 Department of Transfusion Medicine, Ulm University, Ulm, Germany 21 Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-Wurttemberg – Hessen and University Hospital Ulm, Ulm, Germany 22 Microbiology Services, NHS Blood and Transplant, Colindale, United Kingdom 23 University College of London, London, United KingdomHeli Harvalaheli.harvalasimmonds nhsbt.nhs.uk
-
View Citation Hide Citation
Citation style for this article: Nguyen Dung, Simmonds Peter, Steenhuis Maurice, Wouters Elise, Desmecht Daniel, Garigliany Mutien, Romano Marta, Barbezange Cyril, Maes Piet, Van Holm Bram, Mendoza Joaquín, Oyonarte Salvador, Fomsgaard Anders, Lassaunière Ria, Zusinaite Eva, Resman Rus Katarina, Avšič-Županc Tatjana, Reimerink Johan HJ, Brouwer Fiona, Hoogerwerf Marieke, Reusken Chantal BEM, Grodeland Gunnveig, Le Cam Sophie, Gallian Pierre, Amroun Abdennour, Brisbarre Nadège, Martinaud Christophe, Leparc Goffart Isabelle, Schrezenmeier Hubert, Feys Hendrik B, van der Schoot C Ellen, Harvala Heli. SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data. Euro Surveill. 2021;26(27):pii=2100568. https://doi.org/10.2807/1560-7917.ES.2021.26.27.2100568 Received: 11 Jun 2021; Accepted: 05 Jul 2021
Abstract
We compared the performance of SARS-CoV-2 neutralising antibody testing between 12 European laboratories involved in convalescent plasma trials. Raw titres differed almost 100-fold differences between laboratories when blind-testing 15 plasma samples. Calibration of titres in relation to the reference reagent and standard curve obtained by testing a dilution series reduced the inter-laboratory variability ca 10-fold. The harmonisation of neutralising antibody quantification is a vital step towards determining the protective and therapeutic levels of neutralising antibodies.
Article metrics loading...
Full text loading...
References
-
Kellam P, Barclay W. The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection. J Gen Virol. 2020;101(8):791-7. https://doi.org/10.1099/jgv.0.001439 PMID: 32430094
-
Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 2020;370(6521):1227-30. https://doi.org/10.1126/science.abd7728 PMID: 33115920
-
McMahan K, Yu J, Mercado NB, Loos C, Tostanoski LH, Chandrashekar A, et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature. 2021;590(7847):630-4. https://doi.org/10.1038/s41586-020-03041-6 PMID: 33276369
-
Rogers TF, Zhao F, Huang D, Beutler N, Burns A, He WT, et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science. 2020;369(6506):956-63. https://doi.org/10.1126/science.abc7520 PMID: 32540903
-
Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021. https://doi.org/10.1038/s41591-021-01377-8 PMID: 34002089
-
Taylor PC, Adams AC, Hufford MM, de la Torre I, Winthrop K, Gottlieb RL. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol. 2021;21(6):382-93. https://doi.org/10.1038/s41577-021-00542-x PMID: 33875867
-
Piechotta V, Iannizzi C, Chai KL, Valk SJ, Kimber C, Dorando E, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev. 2021;5(5):CD013600. PMID: 34013969
-
Focosi D, Franchini M. Potential use of convalescent plasma for SARS-CoV-2 prophylaxis and treatment in immunocompromised and vulnerable populations. Expert Rev Vaccines. 2021;1-8. PMID: 34015243
-
Libster R, Pérez Marc G, Wappner D, Coviello S, Bianchi A, Braem V, et al. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N Engl J Med. 2021;384(7):610-8. https://doi.org/10.1056/NEJMoa2033700 PMID: 33406353
-
Hueso T, Pouderoux C, Péré H, Beaumont AL, Raillon LA, Ader F, et al. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. Blood. 2020;136(20):2290-5. https://doi.org/10.1182/blood.2020008423 PMID: 32959052
-
Körper S, Weiss M, Zickler D, Wiesmann T, Zacharowski K, M.Corman V, et al. High dose convalescent plasma in COVID-19: results from the randomized trial CAPSID. medRxiv. 2021:2021.05.10.21256192.
-
Kristiansen PA, Page M, Bernasconi V, Mattiuzzo G, Dull P, Makar K, et al. WHO International Standard for anti-SARS-CoV-2 immunoglobulin. Lancet. 2021;397(10282):1347-8. https://doi.org/10.1016/S0140-6736(21)00527-4 PMID: 33770519
-
Cele S, Gazy I, Jackson L, Hwa SH, Tegally H, Lustig G, et al. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. Nature. 2021;593(7857):142-6. https://doi.org/10.1038/s41586-021-03471-w PMID: 33780970
-
Wibmer CK, Ayres F, Hermanus T, Madzivhandila M, Kgagudi P, Oosthuysen B, et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med. 2021;27(4):622-5. https://doi.org/10.1038/s41591-021-01285-x PMID: 33654292
-
Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021;19(7):409-24. https://doi.org/10.1038/s41579-021-00573-0 PMID: 34075212
-
Abani O, Abbas A, Abbas F, Abbas M, Abbasi S, Abbass H, et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet. 2021;397(10289):2049-59. https://doi.org/10.1016/S0140-6736(21)00897-7 PMID: 34000257
-
Ratcliff J, Nguyen D, Fish M, Rynne J, Jennings A, Williams S, et al. Virological and serological characterization of critically ill patients with COVID-19 in the UK: Interactions of viral load, antibody status and B.1.1.7 variant infection. J Infect Dis. 2021;jiab283. https://doi.org/10.1093/infdis/jiab283 PMID: 34031695
-
Perera RA, Mok CK, Tsang OT, Lv H, Ko RL, Wu NC, et al. Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. Euro Surveill. 2020;25(16):2000421. https://doi.org/10.2807/1560-7917.ES.2020.25.16.2000421 PMID: 32347204
Data & Media loading...
Supplementary data
-
-
Supplement
-